Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Krystal Biotech Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. These matters are distributed among 4 examiners and 2 art units, creating a docket with repeated examination assignments within a limited art-unit structure.
NICOL, ALEXANDER W is the busiest examiner, handling 2 pending actions. That concentration makes examiner-specific consistency relevant, particularly when preparing arguments or amendments that may recur across related matters.
The difference between the number of pending actions and the number of examiners shows that some examiners handle multiple matters, while the 2 art units indicate that assignment patterns should also be reviewed at the art-unit level. Counsel can use that structure to coordinate positions without assuming identical treatment across every application.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICOL, ALEXANDER W | 2 | 42.7% | +43.6% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17127416 | COMPOSITIONS AND METHODS FOR GENE DELIVERY TO THE AIRWAYS AND/OR LUNGS | GONZALES, JOSEPHINE MARIA | 37d overdue |
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | KELLY, ROBERT M | 44d overdue |
| 17127416 | COMPOSITIONS AND METHODS FOR GENE DELIVERY TO THE AIRWAYS AND/OR LUNGS | GONZALES, JOSEPHINE MARIA | 37d overdue |
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | — |
| 18829581 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | — |
| 18634382 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1634 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | 1638 | §103§112Other | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18829581 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | 1634 | §103Other | Final Rejection | — | Pending | Sep 10, 2024 |
| 18634382 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Apr 12, 2024 |
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | 44d overdue | Pending | Mar 22, 2023 |
| 17127416 | COMPOSITIONS AND METHODS FOR GENE DELIVERY TO THE AIRWAYS AND/OR LUNGS | GONZALES, JOSEPHINE MARIA | 1638 | §103 | Final Rejection | 37d overdue | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKrystal Biotech Inc. has 5 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Alexander W Nicol has the most, with 2 of Krystal Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
